Published in Antimicrob Agents Chemother on August 01, 1987
Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS) | NCT00073086
Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res (2008) 1.86
Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother (2011) 1.04
The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design. Med Res Rev (2016) 0.80
The threat of avian influenza A (H5N1). Part III: Antiviral therapy. Med Microbiol Immunol (2007) 0.79
Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis. Antimicrob Agents Chemother (2016) 0.77
Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations. Viruses (2016) 0.76
Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science (1972) 7.74
Lassa fever. Effective therapy with ribavirin. N Engl J Med (1986) 6.38
Ribavirin small-particle aerosol treatment of influenza. Lancet (1981) 2.91
Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. N Engl J Med (1969) 2.61
Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA (1981) 2.50
Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers. Antimicrob Agents Chemother (1977) 1.70
Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection. J Infect Dis (1980) 1.21
Clinical evaluation of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) in a double-blind study during an outbreak of influenza. Ann N Y Acad Sci (1977) 0.96
Aminoadamantane-resistant strains of influenza A2 virus. J Hyg (Lond) (1973) 0.89
Occurrence of amantadine- and rimantadine-resistant influenza A virus strains during the 1980 epidemic. Acta Virol (1981) 0.88
Sensitivity of influenza A virus to amantadine. J Infect Dis (1977) 0.84
Factors related to errors in medication prescribing. JAMA (1997) 7.72
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med (1998) 6.75
Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J (2001) 4.93
Influenza virus neuraminidase inhibitors. Lancet (2000) 4.89
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res (2002) 4.85
Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis (2001) 3.69
Activity of aminoglycoside antibiotics aganst Pseudomonas aeruginosa: specificity and site of calcium and magnesium antagonism. J Infect Dis (1973) 3.67
Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother (1980) 3.60
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr (2000) 3.53
Pharmacology of gentamicin in man. J Infect Dis (1971) 3.16
Assessment of signs of influenza illness in the ferret model. J Virol Methods (1989) 3.07
Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol (2003) 2.92
Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res (2001) 2.91
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis (2000) 2.90
Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses. Am J Respir Crit Care Med (1999) 2.76
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med (1995) 2.66
Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol (2001) 2.58
Current therapeutics. 234. Gentamicin. Practitioner (1967) 2.54
Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob Agents Chemother (1983) 2.53
Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA (1981) 2.50
Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother (2001) 2.46
Prevention of Pneumocystis carinii pneumonitis in AIDS patients with weekly dapsone. Lancet (1990) 2.44
Metastatic tumors to the maxilla, nose, and paranasal sinuses. Laryngoscope (1966) 2.43
Risk factors for acute wheezing in infants and children: viruses, passive smoke, and IgE antibodies to inhalant allergens. Pediatrics (1993) 2.41
Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology (1997) 2.37
T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol (1998) 2.31
Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol (2005) 2.28
Outer membrane protein and lipooligosaccharide analysis of paired nasopharyngeal and middle ear isolates in otitis media due to nontypable Haemophilus influenzae: pathogenetic and epidemiological observations. J Infect Dis (1987) 2.21
Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis (1989) 2.21
Laboratory and clinical conditions for gentamicin inactivation by carbenicillin. Arch Intern Med (1972) 2.19
Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis (1990) 2.11
Frequency and natural history of rhinovirus infections in adults during autumn. J Clin Microbiol (1997) 2.09
A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. J Infect Dis (1972) 2.06
Serologic analysis of first-episode nonprimary genital herpes simplex virus infection. Presence of type 2 antibody in acute serum samples. Am J Med (1984) 2.05
Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis (1999) 2.03
Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother (1981) 1.99
Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection. J Clin Virol (1999) 1.98
Ototoxicity of gentamicin in man: a survey and controlled analysis of clinical experience in the United States. J Infect Dis (1971) 1.97
Salicylate ototoxicity; a clinical and experimental study. Arch Otolaryngol (1965) 1.96
Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction. Pediatrics (1998) 1.94
Etiology of acute conjunctivitis in children. J Pediatr (1981) 1.92
Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J Infect Dis (1998) 1.89
Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis (1971) 1.89
Respiratory syncytial virus proteins: identification by immunoprecipitation. J Virol (1981) 1.86
Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2. Virology (1995) 1.86
Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis (1998) 1.85
Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis (1995) 1.84
An evaluation of the use of statistical methodology in the Journal of Infectious Diseases. J Infect Dis (1984) 1.82
Picornavirus infections: a primer for the practitioner. Arch Fam Med (2000) 1.80
Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics (1996) 1.77
Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR. J Clin Microbiol (1997) 1.76
Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin North Am (1987) 1.73
Analysis of respiratory syncytial virus F, G, and SH proteins in cell fusion. Virology (1994) 1.72
Alterations in outer membrane proteins of Pseudomonas aeruginosa associated with selective resistance to quinolones. Antimicrob Agents Chemother (1988) 1.70
Viremia in Asian influenza. Trans Assoc Am Physicians (1966) 1.70
Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis (1987) 1.68
Human rotavirus studies in volunteers: determination of infectious dose and serological response to infection. J Infect Dis (1986) 1.68
Comparison of the Immulok cultureset kit and virus isolation for detection of herpes simplex virus in clinical specimens. J Clin Microbiol (1983) 1.64
Restriction fragment mapping of Branhamella catarrhalis: a new tool for studying the epidemiology of this middle ear pathogen. J Infect Dis (1988) 1.64
Effects of zidovudine therapy in minority and other subpopulations with early HIV infection. JAMA (1991) 1.62
Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother (2001) 1.61
Nasopharyngeal flora in the first three years of life in normal and otitis-prone children. Ann Otol Rhinol Laryngol (1991) 1.60
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS (2001) 1.59
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med (1995) 1.59
Allergic reactions to workplace allergens. JAMA (1997) 1.57
Determination of the epidemiology and transmission of nontypable Haemophilus influenzae in children with otitis media by comparison of total genomic DNA restriction fingerprints. Infect Immun (1989) 1.57
Rapid diagnosis of influenza A and B by 24-h fluorescent focus assays. J Clin Microbiol (1988) 1.57
Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med (1986) 1.56
The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection. Sex Transm Infect (2006) 1.56
Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis (1994) 1.55
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.55
Humoral and cellular response in humans after immunization with influenza vaccine. Infect Immun (1973) 1.54
Evaluation of a possible association of urban air toxics and asthma. Environ Health Perspect (1995) 1.52
Encephalitis associated with erythema infectiosum. J Pediatr (1970) 1.51
Antibacterial activity of cinoxacin in vitro. Antimicrob Agents Chemother (1975) 1.50
Cell-mediated immunity in humans during viral infection. I. Effect of rubella on dermal hypersensitivity, phytohemagglutinin response, and T lymphocyte numbers. Infect Immun (1974) 1.50
Relative concentrations of serum neutralizing antibody to VP3 and VP7 proteins in adults infected with a human rotavirus. J Virol (1988) 1.49
Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother (1999) 1.49
Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob Agents Chemother (2000) 1.49
Effect of isoprinosine against influenza and some other viruses causing respiratory diseases. Antimicrob Agents Chemother (1972) 1.48
Comparative in vitro activity of azlocillin, ampicillin, mezlocillin, piperacillin, and ticarcillin, alone and in combination with an aminoglycoside. Antimicrob Agents Chemother (1979) 1.47
Acute respiratory illness among immunized and nonimmunized patients with high-risk factors during a split season of influenza A and B. J Infect Dis (1988) 1.46
Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy (1999) 1.45
Evaluation of occupational asthma from airborne egg protein exposure in multiple settings. Chest (1990) 1.45
Epidemiologic evidence for Lancefield group C beta-hemolytic streptococci as a cause of exudative pharyngitis in college students. J Clin Microbiol (1997) 1.45
Neutralizing activity in nasal secretions and serum in resistance of volunteers to parainfluenza virus type 2. J Immunol (1968) 1.42
The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA (1994) 1.41
Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (2000) 1.41
First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother (1991) 1.40
House dust (1-3)-beta-D-glucan and wheezing in infants. Allergy (2007) 1.40
In vitro activity of zinc salts against human rhinoviruses. Antimicrob Agents Chemother (1987) 1.40
Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis (2000) 1.40